Saturday 17 October 2026 Export ADMA’s income statement to Excel — free account

ADMA Biologics Inc

ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1.98%, EPS grew 21.4%, free cash flow grew 19.7% and total debt rose 140.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

10.68 0.05 −0.47%

Follow ADMA

Alert me

Market cap: $2.4B
P/E: 14.8×
Fwd P/E: 9.5×
Dividend yield: —
F-score: 5/9
Altman Z: 19.98
Beneish M: −0.17
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.47

Total sells 1.57

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	3	—	—	—	—	—
Sell	1	1	—	1	2	—	—	—	—	—	—	—

Insider Ownership 6.09%

Capital & Financial Ratios $m

Market Cap 2,400.00

Revenue 512.28

Net Income 168.96

Free Cash Flow 116.22

Net Debt 62.89

Current Ratio 6.97

Debt/Equity 0.49

P/E ratio 14.83

Fwd P/E 9.53

P/S ratio 4.76

P/B ratio 5.97

Past 5Y EPS Growth —

This Y EPS Growth 21.30%

Next Y EPS Growth 18.41%

Next Y revenue growth 4.93%

Next 5Y EPS Growth 22.25%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 37.67%

10-year low 10-year high

P/B against its own 10 years 52.82%

10-year low 10-year high

EV/Sales against its own 10 years 27.87%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	51	103	88	136
Receivables	27	50	158	138
Inventory	173	170	206	239
Other	—	—	7	—
	257	331	467	528

	2023	2024	2025	Q'26
Payables	16	20	23	32
ST’ Debt	—	—	—	—
Other	—	—	3	—
	50	56	70	76

Compound Annual Growth %

	10y	5y	3y
Sales	53.17%	64.60%	49.05%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	88.99%	40.16%	46.45%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	114	124	—	—	—
’25	115	122	134	139	510
’24	82	107	120	118	426
’23	57	60	67	74	258
’22	29	34	41	50	154
’21	16	18	21	26	81
’20	10	8	10	14	42

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	58	30	—	—	—
’25	(20)	21	13	36	50
’24	(2)	46	25	50	119
’23	(15)	(6)	12	18	9
’22	(26)	(13)	(13)	(7)	(60)
’21	(33)	(32)	(13)	(33)	(112)
’20	(25)	(21)	(24)	(32)	(102)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	61	22	—	—	—
’25	(24)	19	(1)	34	28
’24	(5)	43	24	47	110
’23	(17)	(7)	11	16	4
’22	(29)	(17)	(17)	(11)	(73)
’21	(36)	(37)	(16)	(37)	(126)
’20	(27)	(25)	(27)	(36)	(115)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.19	0.16	—	—	—
’25	0.11	0.14	0.15	0.20	0.60
’24	0.08	0.13	0.15	0.46	0.81
’23	(0.03)	(0.03)	0.01	(0.08)	(0.13)
’22	(0.13)	(0.07)	(0.08)	(0.06)	(0.33)
’21	(0.16)	(0.15)	(0.13)	(0.09)	(0.51)
’20	(0.26)	(0.23)	(0.19)	(0.20)	(0.88)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4.15	2.01	2.08	2.34	1.45	1.01	1.26	2.95	4.37	13.50	Analyst estimates 2026–2028 Powerpack
	High	8.85	5.79	6.96	6.31	4.65	3.11	3.92	4.65	23.64	25.67
People
People	Employees	92	295	318	314	407	527	617	624	685	647
	Revenue/emp, $m	0.12	0.08	0.05	0.09	0.10	0.15	0.25	0.41	0.62	0.79
Income, $m
Income, $m	Revenue	11	23	17	29	42	81	154	258	426	510
	Gross margin, %	40.34	(28.14)	(148.42)	(34.60)	(45.17)	1.45	22.89	34.44	51.48	57.39
	EBT	(20)	(44)	(66)	(48)	(76)	(72)	(66)	(28)	126	183
	EBT margin, %	(183.05)	(192.26)	(387.06)	(164.50)	(179.41)	(88.52)	(42.77)	(10.94)	29.48	35.80
	Net income	(20)	(44)	(66)	(48)	(76)	(72)	(66)	(28)	198	147
	Depreciation	1	3	4	4	6	7	9	11	9	9
Per share, $
Per share, $	Revenue	0.88	0.99	0.38	0.54	0.49	0.58	0.78	1.15	1.83	2.14
	Earnings	(1.61)	(1.91)	(1.45)	(0.89)	(0.88)	(0.51)	(0.33)	(0.13)	0.85	0.62
	Cash flow	(1.50)	(1.63)	(1.39)	(1.40)	(1.18)	(0.81)	(0.30)	0.04	0.51	0.21
	Capex	(0.01)	(0.12)	(0.05)	(0.07)	(0.15)	(0.10)	(0.07)	(0.02)	(0.04)	(0.10)
	Free cash flow	(1.51)	(1.74)	(1.43)	(1.47)	(1.33)	(0.90)	(0.37)	0.02	0.47	0.12
	Book value	(0.37)	1.76	0.44	0.48	1.02	1.01	0.77	0.60	1.50	2.00
	Shares, m	12	23	45	54	86	140	198	224	233	238
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20.42	29.90
	P/S	5.68	3.32	6.36	7.41	3.98	2.43	4.97	3.95	9.37	8.52
	P/B	0.00	1.87	5.46	8.30	1.90	1.39	5.04	7.54	11.45	9.11
	EV/Sales	5.40	3.19	7.46	9.38	4.96	3.07	5.41	4.29	9.32	8.50
	EV/FCF	(3.14)	(1.82)	(1.96)	(3.44)	(1.83)	(1.97)	(11.35)	275.09	36.11	157.61
Cash, $m
Cash, $m	Operating cash flow	(18)	(37)	(63)	(76)	(102)	(112)	(60)	9	119	50
	Capex	0	(3)	(2)	(4)	(13)	(14)	(14)	(5)	(9)	(23)
	Free cash flow	(18)	(40)	(65)	(80)	(115)	(126)	(73)	4	110	28
Balance, $m
Balance, $m	Working capital	10	53	35	72	134	178	231	207	276	397
	Total debt	18	40	41	85	97	102	154	140	81	76
	Net debt	3	(3)	19	58	41	51	67	89	(22)	(12)
	Shareholders’ equity	(4)	40	20	26	88	141	152	135	349	477
Returns, %
Returns, %	ROA	(82.34)	(66.45)	(66.78)	(44.71)	(45.25)	(29.61)	(21.10)	(8.33)	48.34	26.40
	ROIC	0.00	(65.63)	(97.92)	(30.76)	(31.30)	(18.96)	(11.23)	6.03	26.58	25.69
	ROE	1,073.35	(243.95)	(218.77)	(210.08)	(132.38)	(62.46)	(44.96)	(19.67)	81.65	35.56

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PGEN Precigen, Inc.	$2.6B	— (loss-making)	— (loss-making)	+6,322.66% (above 0%: growing)	n/m	+8.73% (above 0%: growing)	94.90%	41.18%	Compare
BEAM Beam Therapeutics Inc.	$2.6B	— (loss-making)	— (loss-making)	−94.21% (below 0%: shrinking)	n/m	+13.92% (above 0%: growing)	100.00%	(25,827.14%)	Compare
NAMS NewAmsterdam Pharma Company N.V.	$2.5B	— (loss-making)	— (loss-making)	−80.67% (below 0%: shrinking)	n/m	−4.07% (below 0%: shrinking)	100.00%	(1,752.61%)	Compare
MBX MBX Biosciences, Inc.	$2.4B	— (loss-making)	—	—	n/m	−29.67% (below 0%: shrinking)	—	0.00%	Compare
ADMA ADMA Biologics Inc	$2.4B	14.8×	9.5×	+1.98% (above 0%: growing)	+21.43% (above 0%: growing)	+19.72% (above 0%: growing)	69.36%	42.16%
SLS SELLAS Life Sciences Group, Inc.	$2.3B	— (loss-making)	— (loss-making)	−57.10% (below 0%: shrinking)	n/m	−3.52% (below 0%: shrinking)	0.00%	0.00%	Compare
CLDX Celldex Therapeutics, Inc.	$2.3B	— (loss-making)	— (loss-making)	−96.83% (below 0%: shrinking)	n/m	−35.45% (below 0%: shrinking)	100.00%	(366,468.18%)	Compare
AUPH Aurinia Pharmaceuticals Inc	$2.2B	6.9×	16.5×	+18.87% (above 0%: growing)	+81.25% (above 0%: growing)	+19.08% (above 0%: growing)	92.12%	48.19%	Compare
HRMY Harmony Biosciences Holdings, Inc.	$2.2B	12.2×	9.4×	+30.32% (above 0%: growing)	+88.41% (above 0%: growing)	+16.53% (above 0%: growing)	75.81%	34.18%	Compare
Median of peers	$2.4B	—	—	−57.10%	—	+2.61%	94.90%	0.00%

All 614 Biotechnology stocks →

ADMA Biologics Inc (ADMA) key facts

Strength: ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
ADMA Biologics Inc (ADMA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ADMA traded at $10.68, a market capitalization of $2.4 billion.
Return on equity was 35.6% and debt-to-equity 0.49.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 19.98 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.